Charity regisiration number.. 1198095
Compan}. registrdtion number= CE028473
AMMF - The Cholangiocarcinoma Charity
(A Charitable Incorporated Ihganisationl
Annual Report and Financial Staiemen
for ihe Year Ended 31 January 2026
Edmund Carr LLP
Chartered Ac¢ountsnts & Statutory Auditor
146 New London Road
Chelmsford
ssex
CM? OAW

AMMF - The Cholangiocarcinoma Charity
Contents
Reference and Administyative Dethils
Trustees, Report
210 11
Independent Examinerfs Report
Statement of Financial Activities
13
Balance Sheet
14
Stat¢mcn¢ of Cash Flows
15
Not¢5 to th¢ Financial Stat¢rn¢nts
16to25

AMMF - The Cholangiocarcinoma Charity
Referenee and Administrative Details
Chairma
Mr Noel Corrigan
Tru5tee5
Mrs Gillian C(wrigan
Mr Harold Corrigan
Mr Tom Morement
Senior Man3gernent l Leadership Mrs Helen Morement. CEO
Registered Office
Enterprise House
BossingtrA)um Road
Siansied
CM24 IQW
The charily is ineorporaied in England and Wales.
1198095
Ch8rily Rt%istr&tion Number
Company Registration Number
CEO?8473
Independen¢ Exarniner
Edmund Carr LLP
Chartered Accounianis & Stsiutory Auditor
146 Ncw. l.ondon Road
Chelmsford
CM? OAW
Page I

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
The trustees present iheir rewn wilh the financial sthiemenis of ihe chariiy (or ihe year ended 31 January
2026. The irusiees have adopied the provisions of Ateouniing and Repy)rting by Chariiies.. Sthiement of
Recommended Practice applicable to thaiilies pieparing their accounts in accordance with ihe Financial
Reporting Standard applicable in the UK and Republic or Ireland (FRS 1021 (effeciive l January 20191.
AMMF The Cholangiocarcinoma Charity *'as regisiered with ihe Charity Commission as a Charitable
Incorporaied Organisaiion (CIO) during ihe year ?0?? The CIO regisiered number ￿'1th the Charity
Commission is 1198095.
The charity was originally regisiered in ?IM)2 under ihe name. The Alan Moremeni Memorial Fund
(working tille. AMMTr l and was an unincoTpofdted charity with the registrntion number 1091915.
To support the coniinuing grO￿lh of the charity. AMMF'S Trns￿e$ decided that it should transition as a
legal entiij. from unincorpordied regIS￿red chariry sraius io ihai of a Charitable Incorporated Organisation
ICIO). The new CIO siarus ￿a5 approved on O l June. ?0*? Ai ihai poini ihe work and all assets of ihe
original chariry passed io the new CIO chariry.
The ori&pinal chariry and its registered number 1091915 will always remain in existence, with all records
submitted io the Chariiy Commission 5111] available on the Commission's website, but thi5 entity will now
remain in thc backuiround.
The charity. under its CIO status. is otTicially know'n as.. AMMF- The Cholangiocarcinoma Charity.
AMMF 's aims and objeciive5 remain unchangied. and the chariiy's work has conlinued 5eainlessly and
without interruption since ihe incepiion of thc CIO on O l June ?0??
Throu&ihoui this document AMMF refers to the CIO. AMMF - The Cholangiocarcinoma Charity.
Objectives and actvitie5
AMMF'5 MISSION
A world improved for the cholaiigiocarcinoma palieni by the Sharing of knO￿ledge a¢r05s ¢he healthcare
and re5¢arch communities and H'ith the family ofaffected people across the globe.
AMMF's V1510N
A ￿Orld where people liv¢ their lives free of ¢holangiiKwrinoma ICCA) as a lir￿threatenillg disease.
AMMF
the Cholangjooa￿lnQrna CharÉty is th¢ only charitv in the UK solely dedicated to
holangl￿ar(l￿￿ma Ibile durt cancer). AMMF works iiationally throughout the UK, as well as iii Europe,
and collaborates globally.
AMMF 15 wholly committed nationally and internationally to tackling the devastating cancer,
cholangiocarcinorna {CCA) on all fronts and. ultirnately. to help find a cure. through..
SLlPPOrt - Providing information to individuals or group5 to support a patient or loved one along their
joumey
Etnpowemient Empowering patient5 and their loved one5 to advocate for themselves. 5cek better care.
new tieatmetlt options and second opinion5
Acce5S
Advocating equitable access for patients to ensure they have access to the latest treatment
option5 and a tnitlitniitn standard of care appropriate to them
Awareness Raising awareness of CCA io supwi earlier diagnosis. fair and equal access to treatments.
including rtew treatment approaches

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
Research - Encouraging and SUPTX)rting research into causes. diagnostics. and treatsnent for those with
CCA
Policy- Working tow'ards ensuring healih Care p)licies refleci the needs of those with CCA
CCA is under-represenied and under-funded across all areas. including policy. services. and research. li is a
poorly undersiood and under researched disease ￿'hiCh is increasing in incidence nL)i only in Ihe UK but
Ihroughoui ihe world. Lack of awareness and ihe dilTiculiies of achieving clear and accuraie diagnosis.
mean thai mosi are ai an advanced stsge and in0￿rable ai lime of their diagnosis.
Whilst surgery remains ihe only poteniially curative ireatmenL there is now chemoiherapy. tsrgeied
Iherapies and immunotherdpy. and a grO￿l￿g iiuinber of clinical irials. in panicular those investigating
funher iargeted iherapies and immunoiherapies. Ho*'ever. a diagnosis of inoperable CLA remaiiis
invariably fatal. and this is a siiuaiion ihai has nor altered in decades. AMMF is committed to working ro
change this scenario. naiionally and in￿rnatIonally.
Activities
Re501uie in briThging about improvement for the CCA patieni, AMMF conrinues to work closely with
patients and ihcir carers. cliniciank healthcare professionals. researchers, and policy makers. a5 well as
actively collaboraiin& &plobally.
Providing Support And Information
AMMF'S CEO and M¢m￿r5 of ih¢ Ammf team atiended ihe vinual NHS cancer chariiy bTiefin&i meelin&is
throughoui •O?5. These regiular m¢¥'iingJs have proved helpful and infonnative, providing dLtai15 of iiew
dev¥lopments in NHS processes and policies in a timely manner. AMMI-' s M¢dical and Clinical Advisors
are coniacled on a reLiular basis for hllp and advice on ho￿ best io handle the more di￿1¢Ult palien¢ queries
the charil}' receive5, and for upioyla¢e infoThalion oli ¢lini¢al trials.
AMMF'5 w'ebsile ¢(Trnlinued io be UF¥lated regularlv. and pn)vtdes infonnati¢)n on all aspects of CCA.
including ¢reatments and specialists. th¢ advances being made and. importpntly. there is a coinprehensive
list of the ¢linical trials ¢ha¢ are available and recwiling in the UK. which is proving a valuable resource to
healihcaTe professionals and palients. MThw.ammf.org.uk
The charity us¢s a number of SIKial media platforn15
Facebook. X {fonllerl)' Twitter). Ii)stagram.
Linkedln and Blu¢Sky. Th¢s¢ are each kept up to date w'ith daily infomiation of iinportaiice and relevance
to SiiPPQrters. Th¢ number of followers on eaoh ¢i)ntinues to grow. with Facebook in particular n(Trw at (Trver
7,000 follow¢rs.
AMMF'5 three private. metnber only. 5UPPOrt groups on Facebook. Cholangiocarciiiotna Support- UK and
Europe.. for Patients and Carer5. for Patients Only. and for those bereaved. coiitinue to grow. The groups
provide an invaluable resource for patients and their loved one5 and. moderated by three knowledgeable
volunteer5. each group 15 a safe and private space in which to share information. and to help and 5UPPOrt
each other.
The requirement from indiyidual patients and family member5 for specific infomiation regarding specialist
on5111tants and treatrnentS COlltinue5 to increase. With the wider aM"arene55 of the charity. increasing
incidence and 8row.ing recognition of CCA. it i5 anticipated this area of work will continue to expand.
Advocating Access
During the year 2025. the chariiy Continued its adV￿a¢Y worL especially in helping those Hith CCA to
navigate their way io knowledgeable specialists wherever p)ssible.
Page 3

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
Westrninster Reception - On ?6 FebrnaTV. during ChOlangi(￿arCinOma A wareness Month. AMMF held a
reception at the House of Commons. Wesiminsier. Hosted b) Mar>. Glindon MP. presenthiions There given
by AMMF'S CEO Helen Moiement. Kaiie Nicholl. a CCA survivor and n)yal correswndent, and emineni
specialist. Professor John Bridgewaier. Each presenter talled for ihose wilh the power to change policy to
do so to enable a 'Fairei Deal. Faster, for all diagnosed with CCA. More than iweniy MPS. peers. and iheir
researchers and aides. attended ihe eveni. along with representhiives from NHS England. pharmaceuiical
companies and e%pen healihcare providers.
Holyrood - I l June 2025 On I l June 2075. AMMF i¢Kbk the Reihink Liver Cancer campaign io ihe
Scoiiish Parliameni (Holvroodl for ihe first time. calling for a 'Fairer Deal. Fasier, for people diagnosed
with CLA in Scotland.
AMMF drew atteiition to ne￿. daia shoM'ing ihe growing number of ihose ￿'1th CLA iii Scotland. and that
Scoiiish CCA patients were unable io access full molecular profiling as there ￿a5 funding available for
only a single gene fauli. H'hereas ihose in England had access 10 a wider molecular profiling panel.
As a result, some Scottish patients were missing opportunities to acces5 NH&approved life-extendin
targycted treatments and clinical trials. This creaicd inequity comparcd with Engiland. rcsultingT in some
Scottish patients with the means to pay privately accessing iesting and treaunent across ihe border.
At thc reccpiion, hosted and introduced by Beli Macpherson MSP for Edinburgh Northern and Leith.
prcscntations w'erc givcn by..
J¢nni Minlo MSP, Minister for Public Health and Women's Health
Hi.l¥n Morem¢n¢, AMMI.. Chief Executive
B¥iijamin Carey. PaiiLni RLpresenthiiVe for NHS Scoiland's HepatoPancrealoBiliary NelwoTk
Prol¥ssor Tim Kendall. Personal Chair of Liver Paiholog). at ihe University of Edinburgh and Consuliant
Liver Patholo&TiSt at the Royal Infirniary of Edinburgh
The reception was att¢nd¢d by five MSPS lincluding ihe Minister) as w¢ll as people with lived experience
of CCA from across Scoiland. expert healthcare provid￿. researchers and phannaceulical coinpany
repr¢sen¢alive5.
Following the reception. Jenni Minlo MSP (Minisier for Public Heal¢h and Women's Heal¢hl agreed to
onsider a hu5iness case for molecular profiling tests for CCA for thos¢ iii Scotlaiid. and to provide a
formal response. AMMF liaised with the Scolli5h Hepatobiliory Cancer Network. to develop and submit
the busin¢s5 ¢a5¢.
As a resiilt of this, in D¢¢emb¢r ?0?5. Jenni Minto MSP announced that the Scottish Government would be
SUPPOrting the implementation of the molecular t¢sting prograJnm¢ for CCA. Funding would be released in
20?6 to the NHS Scotland Genomic Laboratorie5 to deliver this Service. The testing programme for CCA
was prioritised ahead of w'ider refortns to the 8enornic medicine service.
Raising Awarene5$
The Rethink Liver Cancer Campai
During ?0?5. AMMF'5 'Rethink Liver Cancer. campaign
ontinued. workin8 to broaden tht focus of liver cancel frotn being &Nclusively hepatocellular carcii)oma
{HCC} to highlight that CCA i5 also a primary liver cancer. at]d to ra15e awareness and influence health
policy foi better recognition. earlier diagn05L5. and equitable treattnet]t acces5.
Page 4

## **AMMF - The Cholangiocarcinoma Charity** 

## **Trustees' Report** 

The 2025 initiative under the campaign was the request for "A Fairer Deal, Faster". To promote this request, a photo shoot, 'Faces of Cholangiocarcinoma' was arranged with the celebrity photographer, Rankin, who waived his f for a day's photography at his studio. Eight people with CCA were involved in this, including Zandra R hodes (designer), Katie Nicholl (royal correspondent), Charlie Shrager (model), and others well known to the charity - Ilona Smith, Andrea Sheardown, Andy Clay, Judith Neptial, Benjamin Carey. The individual portraits formed part of the 'Faces of Cholangiocarcinoma' project, which launched at the start of February's Cholangiocarcinoma Awareness Month, and continued throughout 2025 to raise awareness. 

On the day of the shoot, a 'behind the scenes' video was created by Dead Ready, AMMF's video team. AMMF's PR/comms team also recorded individual interviews, and these were used to create a new campaign video, "Rethink Liver Cancer - for a Fairer Deal Faster'' which was shown for the first time at AMMF's Westminster reception on 26 February, 2025. It was also used throughout 2025 at meetings and events where the CEO, Helen Morement was invited to speak. 

• The 'Behind the Scenes video: https://www.youtube.com/watch?v[=] vDZ7mrkl86U • The campaign video, "Rethink Liver Cancer for a Fairer Deal Faster'': 9loCFcubudI https:/ /www.youtube.com/watch?v[=] 

AMMF's awareness raising work during February 2025, especially around the 'Faces of Cholangiocarcinoma' project, achieved a considerable amount of media coverage over the month: 

198 pieces of published/ broadcast media coverage, including: 

• 3 x national TV broadcast (BBC Breakfast, ITV Lorraine and GB News Breakfast) 

• 5 x regional TV news broadcasts (BBC South-East lunchtime and evening; ITV London breakfast, lunchtime and evening) 

• 2 x radio broadcasts (BBC Radio Merseyside and Boom Radio) 

• 13 x national newspaper print features / news stories (Daily Mail, Mail on Sunday, The Mirror, Irish Mirror and Northern Ireland Mirror, Daily Express and Irish Daily Express, Scottish Metro, The Herald, The National, The Scotsman, Daily Record and Morning Star) 

• 13 x features / news stories on national news websites (MailOnline x 3, The Metro, The Independent, Scotsman, Irish News, The Sun, GB News, BBC Online) 

• 5 x print news stories in regional Scottish newspapers. 

• 130 x news stories on regional newspaper websites from across the UK. 

• 3 x BBC Online news stories (featuring Charlie, Zandra and Helen/ Andrea Sheardown / Sian Ashcroft) 

• 19 x news stories on international news websites (including The Mirror USA, msn.com and aol.com) 

• 1 x feature on international lifestyle website (vanityfair.com) 

The combined audience reach was over 865 million 

- **HPB Nurse Study Day 07 May 2025** - AMMF's Hepatobiliary (HPB) Nurse Study Day was launched in 2025 to address a need for nurse-led education and networking opportunities to advance clinical practice and improve patient outcomes. 

The progra e included current and emerging treatments, prognostic assessments, surgical considerations, clinical trial consent and care, and an international overview of HPB nurse roles and responsibilities. This progra e was approved by the Royal College of Nursing, who gave an accreditation of3.5 hours. 

AMMF was grateful to receive fmancial sponsorship for the Nurse Study Day From AstraZeneca and The Access Foundation. 

Page 5 



AMMF - The Cholangiocarcinoma Charity
Trustees, Report
AMMF'S EuropeaTh ch0langiocarci￿0m￿ CoDfereNce 07 - 09 May 2025 was a three•day hybrid event
showcasing groundbreaking reseaith. innovative ireaiments. and the eollaboraiive spirii of the CCA
community.
The chariTh' N'as delighied to ￿elcOMe No iniemaiionallj renO￿ned specialists ai the fL)refront of the CCA
'orld. Ms Rachel Guest (surgeon. Edinburgh) and Dr Hein7-Josef Kjumpen {oncologist. Ams￿rdam1. as
C￿chaIrS of ihe ?0?5 conference. The). expertly hosied a faculty of 40 internaiional speakers and managed
some challenging Q & A sessions. all exploring ihe conference iheme.. "A Fairer Deal. Faster"
As in previous years. Ihe conference broughi togeiher a diverse audience. including healthcare
profes%ionals IHCPS). researchers. medical siudents. paiieni organisaiions. parients. carers and patient
advocaies. This mix provided a unique plaiforn) for exchanging knO￿ledge and per5￿ctiVeS, enhancing ihe
undersianding and management of CCA.
Impactful personal perspectives were shared by ihree CCA patients and one carer. Their powerful
individual stories hi&Trhlighied real-m'orld challenges including the cNcial Iieed for specialist knowledge.
early diagynosi5, comprehensive support sysrems and the im[rf)r￿nCC of ensurinky equity in diakTnosis and
managTcmcnt for all, rcgyardless of who ihey are or where they live.
AMMF'S conference was endorsed by the BSC {Briiish Society for the Study of the Liver), and was a CPD
accredited event. worth 19.5 hours CPD Iconlinuing Professional Development).
AMMF was grateful ¢0 receive financial sponsorship for the eveni from the pharniaceutical organisation5'.
Astrazeneca, Jazz Phamiaceulica15. Taiho Oncology Europe. Servier. and Boehringer Ingelheim.
The full pro&Tramme and all conference presentalions from the three days ￿ere recorded and reinain
available to view via AMMF'S website. See.. hiips-Ilammf.org.uklammf￿onr¢renc￿209sI
Public Bcnefit
IM lomiiti& ¢h¢ charily's (Trbj¢ciives and plonning the a¢tivitie& the Injsiees have considered the Charity
Commission's guidance iii r¢sp¢cl of publi¢ benefit.
Acheivements and perforrna Trce
Supporting Research
AMMF. remaiii% conimitted to supporting research inlo CCA. In 20?5. based on the advice of AMMF'S
Scientific Advisory Board. awards w¢re offered and ac¢ept¢d by the fourteen instltutions to 5UPPOrt their
r¢search into CCA..
AMMF'5 Research Aw2rd$
In ?0?5. aw'ards w'eTe offered and accepted by the follow'ing to 5UPIM)rt their research into CCA..
Vniversitv of Lei¢e$t¢r {Dr Ed Jgrmanl AMMF Ref- 20251227
Re5carch.. Doc5 COX? pattern thc local immune cTri'ironinciit to promote early neopla5tic grow1h?
Award.. £50.000 (to be given in two in5talments)
Sapienza Universitv of Rome {Dr VeroDiCa Porreca) AMMF Ref - 20251228
Re5eaich.. Targetins the adhesive function5 in inttzhepatic CCA prOg￿5S1on.. focu5 on the cancer cell
surface receptors engaged by the THBSI and THBS?
Award.. £40.000 (to be given in two in5talrnents)
Henri MoNdor UDiversitY Hospital (Prof JulieD Calderaro) AMMF Ref- 20251229
Research.. AI-CCA.. Artificial Intelligence as a Biomarker for Intrahepatic CCA
Page 6

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
Award.. £44.000 lio be given in insialments)
Universitv of Edinburgh {Dr Rachel Guest} AMMF Ref - 20251230
Research." The role ol IDH muiaiion in lil'er cell plasiicil%' and Inirahepatie CCA
Award". £97.i48.37 (to be given in insthlmenLsI
Wtlleome Sanger Institutt {Dr Ashrav Gunjur) AMMF Rtf - 2025ll31
Researeh.. The immune implications of inird-iumoural bacieria in CCA.. a translational research siudy using
samples trom the 'CheckPAC' phase 11 clinical trial
Aw'ard.. £16.780.00 (io be given in one insthlmeni)
University College London (Prof John Bridgewater) Ref- 20251232
Research.. Integiraiion of SAFIR-ABLIO da￿ inro (he ENS-LCA da￿base
Award.. £?0.503.ou iio be given in one insthlineni)
Universitv ol Birmingham (Mr Kav*ni Kavani) AMMF Rtf - 202V233
Rcsearch.. Siablc fujiciional Induccd Tregjs ISFiTrcgysl.' A iiovcl me￿}5 of immunosuppression for patients
Iransplanted for CCA iii ihe crn of iransplani oncology
Award.. £99,317.67 (io be given in one in5talmenl)
University of Nottingham (Prof%heela Jai'aramanl AMMF Ref - 202W234
Research.. New approaches for improvLd sicni paicncy and iumour cell killiiig
Award.. £75.504.37 (io be gyiven in Ihr¢e instalmenlsl
During 2025 the following pa)'ments were made re existing awards:
Unii'er5it J. of GlasRow- AMMF ref: 20231218
£49,73•.00 was paid on ?3.03 ?5 rLprLsiniing ¢he second InS￿lment of the award of £99,464.00 aLireed ¢0
fund the work.. Id¢nlifving iherapeutic opportunities for Biliary Cancers by investigating ihe Tole of
Monocytes in d￿g r¢spons¢.
Uni%'crsit)' of Oxford - AMMF Ref: 20231219
£56,00•.57 was paid 011 17.06.70?5. T¢PT¢seiiling full pavment of the award of £56.00? 57 agreed to fund
the work.. Normal cholangi(KJle ¢ontainm¢nt of CCA through tn¢thboli¢ and tr￿)ScrIptoM]C regulatioii
Sapienza Universit). of Rome- AMMF Ref: 2022nl I
£211.939.06 paid 011 14.11 ?0?5. the s¢coiid athd filial ijistalmenl of award of £35.000.00 for th¢ ￿Ork..
The rol¢ of "fHBSI. THB52 and PE"Dk in the lymphatic dissemination of the intrah¢patic CCA..
identification of downstream signalling
S8pienz8 Universit) of Rome- AMMF Ref: 20251228
£20.399.37 wa5 paid on l? l ? ?0?5. the first instalnient of an award of £40.1)00.00 for the work.. Targeting
the adhesive fiinction5 itl intrahepatic CCA progression= focus on the cancer cell surface receptor5 engaged
by the THBS l and THBS2
Universitv of LiveTpooI- AMMF Ref: 20231217
£1? $00.00 w'as paid otl ?? I? ?0?5. the fiT5t in5talment of an award of £25,000.00 for the work..
Interrogating tumour-mediated immunosuppre55ion in PEri-hilat CCA
Henri MoNdor University Hospital- AMMF Ref: 20251229
£19.753.02 wa5 paid on 22.1? ?025. the fi￿1 in5taltnent of an award of £44,000.00 for the WOTk= Artificial
Intelligence as a Biomarker for Inirahepaiic CCA
Page 7

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
AMMF'S External Collaboratio
The charity is recogniLed Th'idel),. nationally and iniemaiionally. amongsi tM)th the generdl public and
within medical circles. for its work in ihe field of CCA. and is (requenily invited to become part of Siudy
groups and advisory boards. for example. Ihe w'orking group for Liver Transplantstion for CC.A, and the
executive committee ofccA-UK.
AMMF is also a member of ENS-CCA (European NeN'ork for the Study of CCA), an association of
research groups from across Europe and bes'ond. activels ￿o￿K.1ng on basic. translational. and clinical
research in(0 CCA. and AMMF'S CEO is cfrchair of ihe ENS-CCA Paiient AdV(￿aCY Committee.
The Global Cholangiocarcinoma Alliance IGCA) %as esthblished ar AMMF'S intemational workshop held
in London in *018. The aim of ihe Alliwice is io pr()vide a uniied i'oice ihrough inieniational collaboraiion,
rdise the global awareness of CCA and to improve ihe educaiion of both healthcare professionals and
patients.
Since the GCA'S incepiion in *018. AMMF has acied as rhe noi-for-profii partner in this venrure. and
AMMF'S CEO Helen Moremeni is a C￿chaIr on the inicniaiional $￿eringY committce.
During ?0•5. the role of secre￿rIal of ihe GCA and the orgyai)isation of the annual World
Cholankiiocarcinoma Day in February.. Cholangyiocarcinoma A*'arencss Moi)th. passed from thc hcalthcarc
communications agency AXON io Colab Healih who will now also manage the bespoke website and social
media accounts.
AMMF continues ¢0 be an aciiv¢ member of Cancer5? Ihe alliance of rdre and less common caiicer
OTgTanisa¢ions in the UK, which provides Ihose 0￿janIzatIonS with a presence and a voice wiihii) every
national cancer ini¢ialiYe. Ammk's CEO. Helcn MorLYn¢ni was apwinted a board diTectorltrustce of
Cancer32 in 2014 and continued in that role until She resigned in AuL?ust 2025.
Gallbljdder Guidelines and Dala Projcct- Professor Dhaiin), Gorn¢z of Notlinghwm University. the lead
on th¢ new BSG IBriiish Sociely of tiasiro¢nlerologN') Guidelines for ¢h¢ Diagnosis and Mjnageineiil of
Gallbladder Cancer. asked Hel¢n Moremenl. AMMF s CEO. to be pari of the leain preparing the
guid¢line5, and for help in providing dala.
As th¢r¢ was n(Tr separate robust dath for gallbladd¢r cancer. but AMMF s owii r¢c¢ntly ¢ompleted ond
published data project for CCA had included the oiher biliary tract canc¢r% gallbladder canc¢r. ampullary
anc¢r
HDI IHealth Data Insight CIC) Mho prepared that work. were ask¢d by AMMF to provide a
Stand-alon¢ d(Kurn¢nt on gallbladder canc¢r to 511PPOrt guidelines work". Th¢ dwum¢nt, 'F.pid¢miology and
Treatment of (Jallbladder Canc¢r in England 20(Tr1
?0?2. was prepared Imid ?0?5 aiid Submitted to the
t¢am working on the gLiidelines. A5 at th¢ end of?0?5. work th¢ guid¢liiie5 was ongoing.
Centres of Cholangi0¢8rcinom8 Experti5¢
Work on preparing a rationale for Centres of
Cholangiocarcinoma Eipcrtisc. M hich bcoan in ?0?4. continued during the year. The steeriiig coniillittee,
con51Sting of rncrnbers of CCA-UK and AMMF. decided that. based on the geogrdphical inequitie5
uncovered by AMMF'5 CCA data projecL a first step should be to explore ho￿. best to audit hospitals
acr05S the UK to ascertain the number5 of CCA patients each wa5 seeing and what treattnent pathway5
were followed.
SeveTal organisations M'ere approached to piovide a proposal at]d budget for undettaking thi5 M'ork. HDI
(Health Data Insight CIC) w.ere selected for their knoM"led8e and experience in preparing and managing
such an audit. and foi thcii c05tings. Reqiiests m.ere submitted to industry for ￿nding to SUPPOrt this part of
the Centres of Expert15e project. and AMMF agreed to act a5 secretariate and to manage the fi]nding aspect.
This work was ongoing as a( year end.
Page 8

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
National Cancer Plan- AMMF submiiied evidence f(w ihe DHSC (Department of Health and Social Care}
consultation
April
?O?j.
The
submission
available
on
AMMF'S
websiie
hltps.'//ammf.org.u￿2o2s/04lollShap1n8-lhe￿ntw-naII0na1wCartCer-p1a1
AMMF also participaied in two workshops with DHSC to further emphasise the charity's prioriiies..
In-person workshi)p beNeen DHSC and Cancer5? members in April ?025.
• Virtual w'orkshop between DHSC and One Cancer Voice members in July 20?5.
In August ?0?5. two of AMMF'S members joined One Cancer Voice (a Cancer Research UK initiative)
outside Westminster. supw)rting the call for an ambiiious. funded National Cancer Plan.
At ihe year end. publication of ihe Naiional Cancer Plan which had been expecred in November, was
pushed back uniil early in ihe New Year.
New therapv appr4i$als- During ?0?5. AMMF ￿a5 inviied National Insiiruie for Care and Excellence
INICCI to submit Mrittcii and ordl sialemciits iii support of the folloii'ing lic*, therapy apprai5als'.
Zanidatarnab.. for thosc ￿1th an advanced HER-2 wTrsiiivc CCA. AMMF submittcd cvidci)cc for the
apprdisal iii July ?0?5. This included commcnts from paticnts and iheir carcg?ivcrs wilh firsr_hai)d
expericnce of zanidaiamab. and results from an online survey AMMF conducicd ￿hleh achievcd 70
responses. Two AMMk' reprcscniaiivcs. noMina￿d io rcprcseni paiicnts. spoke ai the Cominittee Meetin
on 09 December ?0•5. Ai the )'ear end, Ihe ouicome siill awaiied.
Larotre¢tinib'. a largeled trealment for NTRK-fusion posilive solid tumours {approx 10/0 of CCA
pati¥nlsl. AMMF submiiiLxl ¢vidcnce io the NICE apprdisal in Ociober 20?5. The appraisal Coinmittee
Meeting 15 scheduled for March 20?6.
External Evf nt5
A5 AMMF coniinued to expand its work ihroughoui ihe UK. into Europe and beyond, during 2025 the
hari¢y Teceived a nuinber of invitalions to allend an(Vor to speak about CCA and the Charity's work at
national and iiiteniational conferences including..
17 Januar) 202$
EN&CCA I Precision BTC N¢t￿Ork (European Netw'ork for ihe Study CholAngiocarcinoma I
Precision Biliar). Tract Cancer Nelmork)
Heleti m0￿Ment gav¢ a pr¢senlatioii oil the various palienl r¢sourc¢s AMMF had joiiitly produc¢d with the
Precision BTC N¢twork.
. 2{￿22 Febru&ry 2025
EASL (Europcan Association for the Study of the Liver) Liier Cancer Surnmit. Paris.
Helen Morement attended this meeting and gave a pre5entatioii oli the itnportance of the n)ultidisciplinary
tearn in deciding treatment tyathwaJ'5 and the care of the CCA patient. Natasha Pite ai)d Sabita Maharaj, a
metnber of AMMF s Clinical Nurse Advisor). BoariL a150 attendetL and Sabita spoke about her work a5 a
nurse caring foi thosc with CCA.
10 March 2025
Cholangiobotics Project Conference and Launch ETrent. Nottingham UniveT5ity.
Noel Cotri¥an. Chair of TTU5tee5. and Helen Moiement. CEO. attended to represent AMMF at the event
launching thi5 project.
Page 9

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
I I April 2025
CholangiocarciThorna ConfereMce- IDterThational CoDseDSU5 Research Priorities
Salt Lake Ciiy. USA.
Helen Moremeni was inviied to be a Cowchair of the PatientslAdvocaies and Supportive Care Working
Group la￿ in 20?4. attending a number of preparatory. meeiings. and working with oihei advocates on a
number of topics ro be presenied ai the Cholangiocarcinoma Foundaiion's annual conference ?0?5. During
Ihe conference. Helen presenied on No topics re the CCA paiieni. Nuiriiion. and the ImpL)nance of ihe
Clinical Nurse Specialisi.
. 22-23 Mi)y 2025
Precision-BTL Net￿.ork Annual Meeting- Liquid Biopsy in Biliary Tract Cancer.. From Bench ro Bedside.
Palma. Mallorca
Helen Moremeni was a panel member in discussion group& and also presented ihe work of AMMF.
• 08- 10 October 2025
Annual AUGIS. Scientifie Conference. (Jlasgow
{' Associaiioii of Upper Gaslroiiiiesrinal Surgvery of Great Britain and Ireland)
Heleii Morcmcni attcndcd to present on ihe topic: Thc successes and hardships of a cancer charity - the
journey.
17- 111 November 2025
Astrazeneca Patient Advocacy Leaders. Sumrnit. Cambridge. UK
Heliti Mor¥m¥nt alt¥nd¥d io r¥pr¥sL'ni AMMF ajid lh¢ CCA patienl in discussions and at various breakout
meeting5 during the two day meetin&
01-02 Deccmber 2025
Ch0lanRi￿arel￿0rna-UK Annual Scicntific Mcetin2. Noitingham.
Hellii MiirLmLni and AMMF s Paul 110i4.ard Oi¢LiidLxl Ihis meeiin¥. Helen 15 a member of the Executive
Commi¢te¢ of CCA-UK. and look part in panel dis¢ussion$.
12- 13 Decembcr 2025
European Ad%'ocacy Groups Mc¢tinkL V¢nic¢. Italy
At ihe invitaiion of Apic. Ihe Itolian palients. advocacy group. Helen Morement and Noel co￿lgan
attended the inaugyural meeting of k"uropeaJi adv￿acy group5. Noel ¢haired the me¢tii)g and Heleii
Morem¢nt presented th¢ work of AMMF.
22-24 January 2020
EA.SL (European Associa¢ion for the S¢udi of ¢he Liver) Lii'er Cancer Summit, Edinburgh. UK
Heleii Morement atteiided this ineelin£ to cfrchair the Q&.A discus%ions fallo￿lI1g th¢ plenary 5¢S5ion'.
CCA and rare liver thmour5'. patho8enesis and tredtment.
LOOKING TO 2020
Arnongst our planned events ￿111 ￿-
The Rethink Liver Cancer Campaign and Westrninster Reception 21126
The Rethink Liver Cancel catnpaign LS ongoing and ii.ill continue into ?0?6. especially during February's
Cholangiocarcinoma AM'arene55 Month ￿"ben we m.ill be holding a further reception in Westminster. iii the
House of ComTnon5 Churchill Rootn. This event w.ill once again be hosted by Mary Glindon. MP for
Newcastle upon T￿￿e East and Wallsend. We plan to launch 50tne new. powerful videos from patients and
carers to ut]derlint the need for policy change.
Page 10

AMMF - The Cholangiocarcinoma Charity
Trustees, Report
Centres of CholaNgiocarcinoma Expertise - The work on ihe hospithl audit will continue. The Ou￿ome$
of ihe CCA data projeci and ihe publieation ofihe new" BSG Guidelines for the Diagnosis and Management
of CCA gave AMMF the ammunition to begin w.ork towards building the case for Cenires of CCA
Expertise. During ?0?5. a sieeiing group ofspeeialists in CCA. along wilh AMMF. has been working with
HDI in planning and preparing a quesiionnaire for a hospitsl audit w ascertain ihe numbers of those
diagnosed wilh CCA and the irvdiments ihey aciually receive. St is planned this audit should begin during
AMMF'S European Cholan2iocareinoma Conftrenee 2026- The 20?6 conference ￿.111 take place 13-15
Ma}, w'iih a global taculij and cfrchairs. Professor Brian Daiidson IUKI and Dr Angela Lamarca (Spainl.
two intemationally renowied specialists ai the forefroni of the CCA world.
AND FINALLY
AMMTr has &Frown steadily over the years and. with ihe continued help of lol'al fundraisers and supponers.
sponsors and advisors. we will coniinue our work and remain fully commilled ro achieving a far betier
future for all those diagnosed with CCA.
At thc heart of everything we do is the CCA palienr and iheir families, and each and every, day all of us at
AMMF strive iowards thai impr()Ycd fuiure for all ihose diagnosed with this most challenL¥ing of cancers.
AMMTr' will coniinuc lis work uniil ihai ¥yoal is reached.
FINANCIAL RF.VIF.W
Financial review and reitrvfs policy
ThL Lharii} has coiitinuLd io SirLn￿lih¥n its financial position during the year.
The charity ensures that sufficient reserves are relained in an appropriate fomi io fund its current
obliLtations.
Where Specific r¢se8rch proj¢¢ts hove been secured. Ihe iruslees designate sufficient unrestricted reserves
to cover ihe expeci¢d full1￿ grants payoble over the term of th¢ research projecl.
Structure, Governance and Management
Goi'erning document
The charity is ¢onlroll¢d by its governing documenL ond ¢imstituteS on in¢orpornt¢d charity.
2 No¥ember 2026
Approved by order of lh¢ board of iruslees on ................-............ and signed on its behalf by..
Noel Corrigan
Noel Corrigan- Chair of Tru5tee5
Page 11

AMMF - The Cholangiocarcinoma Charity
Independent Examiner's Report to the trustees of AMMF - The Cholangioeareinoma
Charity
I report io the chariry irusiees on my examinaiion of the accounts of the charity for the year ended 31 January
2026 which are set out on pages li 10 25.
Responsibilities and basis of report
As ihe chariiy's trustees you are responsible for ihe preparaiion of ihe accounts in accordance with the
requirements ofthe Charities Aci 2011 ('the Ati.).
I report in respect of my e%aminaiion of ihe chatilv s accounts eartied oui under section 145 of ihe Act and iii
carrying out m> e.xamination I have followed all the applicable Dlretlions given b> ihe Charii>' Commission
under seciion 145(5Xbl of the Aei.
Independent examiner's statement
Since the eharity's gross in¢om¢ ¢x¢¢eded £?50.(M)O your ¢xamin¢r must b¢ a memb¢r of a body listed ii)
se¢tion 145 of the Act. I confirm thai l am qualified to undertake ihe elaminatioii b¢¢ouse l am a m¢mb¢r of the
Ass(Kiation of Charter¢d CerlifL¢d Accountants. M'hich is on¢ orth¢ list¢d bodi¢s.
I hav¢ ¢ompl¢t¢d my examination. l ¢onfim thot no mat¢rial matt¢ts hav¢ come to my atten¢ion in ¢oiinectioii
with ihe examination giving me cause io believe that in any maierial respeci..
accounting records were noi kew in respect of the chariry as required by section 130 of the Act.. or
the accounts do not accord wilh those records: or
the accounts do rtot ¢ornply w'ith ih¢ applioable requirements ¢on¢eniin& ihe forim and ooiileiii of
accoiints set out in the Charili¢s (Accounts and Report51 Regulaiions ?008 oth¢r ihan any r¢quireineiil
that th¢ accounts giv¢ a 'tru¢ and fair vi¢* Mhich is iiot a niatt¢r consid¢red 95 parf of aii iiidep¢nd¢nl
examination.
I have no concerns and have come across no other matters in connection with the examination to which atteiitioi)
should be drdwn in this repon in order io enable a proper undersianding ofihe accounts 10 be reached
Sandra Morrell
Sandra Morr¢ll FCCA
146 New London Road
Chelmsford
Essex
CM2 OAW
3 November 2026

AMMF - The Cholangiocarcinoma Charity
Statement of Financial Activities for the Year Ended 31 January 2026
(Ineluding Income and Expenditure Aeeount alld Other Comprehensive Ineome)
Total
2020
Total
2n2>
Unrestricted
Restricted
Note
Income Endowments frojn:
Donaiions and legacies
Other trading activities
Investment income
674,438
19.?00
?1.85?
38?19
912,657
19.900
21.852
1,019.470
6.422
19.9?9
Total incom¢
715,490
?j8?19
95i.709
1,04.S.8?1
Expenditure on:
Raising fiinds
Charitable activities
9.608
584,378
9.608
995.993
2.703
818.729
411.615
Toial c¥penditure
593,986
411.615
1,005.601
8•1,43?
Nei incomellexpenditurel
Transfers between fLinds
117J.i96)
39.114
151,8921
??4.389
139.114)
Nei movement in funds
(134,?82)
151,89?)
??4,389
Reconciliation of funds
Total fLinds brou&h( fon¥ard
Total funds ¢arri¢d forward
1.11? ?45
147.539
1 ?59.784
1.035.395
17
1.194.035
1 ?07.89?
1 ?fj9.784
All of the charity's activities derive from continuing operati(Trns during the above two periods.
Page 13

AMMF - The Cholangiocarcinoma Charity
{Registration number: CE028473)
(Charity number: 1198095)
Balanee Sheet as at 31 January 2026
2026
2025
Note
Fixed assets
Tangible assets
10
9.(M)I
7,783
Current assets
Stocks
Debtors
8.827
45.387
1,3?6.?36
9.839
12
Cash at bwik and in hand
13
1,394.776
1.380.450
1,489.902
Creditors: Amounts falling due wiihin on¢ Year
14
{181.559
?37.901
Net current 855ets
1.198.891
?5?.00 I
Nel a55et5
1 ?07.89?
1 ?59.784
Funds of the ch4ri¢y:
Restrictcd income fund5
Res¢ric¢ed funds
17
147.539
Unre5trieted income funds
UnTe5tricted funds
1.194.635
1,11? ?45
Total funds
17
1 ?07.89)
1 ?59.784
The financial statements on pages 13 to 25 were approved by the trusiees. and authorised for issue on
2 November 2026 and signed on their behalf by..
Noel Corrigan
Mr Noel Corrigan
Chaimian
Page 14

AMMF - The Cholangiocarcinoma Charity
Statement of Cash Flows for the Year Ended 31 January 2026
2026
202S
Note
Cash flows from operating activities
Net moveTnent in funds per SOFA
(51.892)
2?4.389
Adjuslmenls
D¢pr¢ciation
Investment income
6.406
i.432
(19.929)
(67.338)
207.892
Working capital adjustments
Decrcasc,lincrcascl iii siocks
Decreasellincreasel in debiors
(Decreasellincrease in creditors
IDecreasellinereas¢ in d¢ferred income
1.012
39.900
151.34?)
5.0001
13,?04)
115,654)
25,737
2.S.000
12
14
Nei cash flows from operating activilies
18? 768
?39.771
Cash flows frum inve5¢ing 8clivi¢ie5
Int¢r¢st r¢ceivabl¢ and similar income
Purchase of tangyible fixed assels
?1.857
7.6?4
19.929
6,996
10
Nei cash tlow's from invesling activilies
Nei IdecTease Jlincrease in cash and cash equivalen15
168.5401
?5? 704
Cash and cash equivalents al l February
1.394.776
1,14?.07?
Cash and cash equiYalerb(s at 31 January
1.376.?36
1.394.776
All of the cash flows are derived from continuing operations durin8 the atmive two periods.
Page 15

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
l Aeeountimg polities
Statement of cornpliaDce
The accounis {financial siaiemenis) have been pw)ared in accordance with the stsiement of Reeommended
Practice." Accounting and Reporting by Charities preparing iheir aecounts in accordance M'ith (he Financial
Reponing Siandard applicable in ihe UK and Republic of Ireland IFRS 102) issued on 16 July 2014 and ihe
Financial Re￿rting Siandard applicable in ihe Uniied Kingdom and Republic of Ireland IFRS 10?) and ihe
Chariiies Aci 201 l and UK Generally ACCep￿d Practice as li applies from l January 2019.
The accounts Itinancial siaiemenisl have been prepared to give a 'inJe and fairf view and have depaned from ihe
Chariiies (Aceounis and Rewrts} Regulaiions ?008 only io ihe required io provide a true and fair view,.
'I'his departure has involved folloii'ing Accouniing and RcrA)rting by Chariiics preparing their accounts in
accordance wilh ihc Financial Rcwjrting Siandard applicable in ihe IJK and Rcpublic of Ircland IPRS IO*
Issucd 011 16 July *014 raihcr ihan ihe Accouniing and Rcponing bj. Chariiies.. Sthiement of Rccommcnded
Practice effective from l April ?005 which has since been withdrawn.
Basis of prepAration
AMMI.- 'I'hL Cholanbiiocarcinoma Charity meets the definiiion ora public benefii eniity under FRS 102. Assets
and liabilities are initially recogynised ai hisiorical cost or wdnsafflion value unless othenvi5e stated in the
relevant accountin& policy noles.
GoinE tothtern
The irusiees consider thai there are no maierial uncenainiies aboui ihe chariij's abilit}, io continue as a g?oing
concem nor any significanl areas of uncenainiy thai affeci the carrying value ofassets held by the chariiy.
Ineome and endowmenis
All incL7me is recognised once ihe charii). has entiilemeni io the income. il is probable that the income will be
received and the amoun¢ of the income receivable can ￿ measured reliably.
Donqliov.T lexq¢'ie.s
Donation5 ar¢ re¢ognis¢d w'h¢n th¢ charity has beeli iiotifi¢d in writing of both th¢ amouiit and s¢ttl¢m¢nt date.
In thc evcnt that a donation is subjcct to conditions that rcquire a Icvcl of performance b). thc cliaritv bcforc thc
charity 15 Clltiilcd to the fund5. the income is dcfcrrcd and not rccogn15ed until cither thosc conditioi)s arc fully
mct, or thc fuifilmcnt of those conditior15 is M'holly within thc control of the charity and il is probable tliat thcsc
condition5 w'ill bc fulfilled in thc reporting period.
Deferred Income
Deferred income represents amounts received for fuiure per1￿JS and is released io incoming resources in the
period for which. it has been received. Such income is only deferred when=
The donor specifies thai the granl or donaiion musi only be used in fuiure accounting periods- or
- The donor has Im[￿￿ed conditions which must be before the charity has uncondiiional entitlement.
Inveslpnenl imrome
Dividends are r¢cognised once the dividend h&5 been declared and notification has been received of the divid¢nd
due.
Page 16

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
Expenditure
All expenditure is recognised once there is a legal or constrnctive obligaiion to that expenditure, it is probable
senlement is required and ihe amount can be measured reliablv. All costs are allocaied to the applicable
expenditure heading thai aggregate similar to ihai Ca￿gory. Where costs cannot be direcily affributed t
panicular headings they have been allocaied on a basis consis￿nI ￿1th the use of resources. ￿1[h central staff
costs all(￿ated on the basis of lime spenL and depreciaiion charges all(KaTrd on the portion of ihe asset's use.
Other siippon cosis are allocaied based on the spread of sthff costs.
RalJingfund
These are costs inciirred in attracting volunlary in¢orn¢. th¢ mona¥wn¢nl of inv¢stm¢nts and thos¢ incurrcd in
trading activities that rais¢ fund5.
Charilable deilvllles
Chariiable expenditure comprises those costs incU￿ed by the charity in the delivery ofits activiiies and services
for ils beneficiaries. It includes both costs that can be allocaied directly io such activities and ihose cosis of an
indireci nature necessary, (o support them.
Governanc¢ ¢oslS
Thesc iiicludc the costs ai(ributable io the charity's compliance with consiiiuiional and staiutory requirements.
includinbi audit. straic&>ic manabpemeni and irusices mceiings and reimbursed cxpenses.
Tangible fixed 85$¢¢$
Individiial fixed assets cos11n￿ £50.00 or more are iniiially recorded at cost. less any subsequent accumulated
deprccidtion and subsequeni accumulated impaimien( losses.
Depreei#tion #nd 8rn0rt15alion
Depreciation is provided on ian¥ible fixed ass￿$ so as io Wri￿ oif the cost or valuaiion. less any estimaied
residual value, over their expected useful economic life as follo￿$..
Asset class
Compiiler equipment
Deprecia¢ion rnethod and rate
33/0
Stock
Stock 15 valued at the lower of cosi and estimated selling price less costs to complcte and sell. after due regard
for obsolete and slow moving stocks. Cost 15 detcnnined using the fir5t-in. fLISt￿ul {FIFO).
Trade debtors
Trade debtors are amounts due from cu5tom¢r5 for mcrchandi5e 501d or 5ervice5 pcrforn)ed in the ordinary
ourse of busine5S.
Trade debiors are recognised iniiially at the transaciion price. They are subsequently measured at amortised cost
Using the eff¢ctive inieresi meihod. less provision for impaimieni. A proii5ion for the impairnient of trade
debtors is established when there is objeeiive evidence tha( Ihe charit>. m.ill noi be able to colleci all amounts due
according to the original temis of the receivables.
Page 17

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
Cash and cash equivaleNt5
Cash and cash equivalents comprise cash on hand and call dew￿lts, and other short-ierni highly liquid
invesiments thar are readily convertible io a knowi arnouni of cash and are subjeci to an insignificant risk of
change in value.
Trade creditors
Trade crediiors are obligaii(FnS 10 pay for giKKis or services ihai have been acquired in ihe ordinary course of
business from suppliers. Accounis payable are classified as curreni liabiliiies if ihe charity does noi have an
unconditional right. at thc end of the re[￿ing ￿riOd. io dcfcr scrtlcmcnt of the crcdiror for at least twelve
months after thc reponing daic. If ihcre is ali uncondiiional righi ro defer settlement for ai least N'elve moiiths
after the reponing date. Ihey arc prescnicd as non-curreni liabilirics.
Tradc crcditor5 are rccogniscd initially ai the wansaciion price and subsequently measured at amortised cost
using the effcctivc intcrcsi mcihod.
Fund structure
Unr¢stTicied income funds are generdl fund5 lh* available for use at the Iruslces's discrelioii iii furtherance
of the objectives of the charity.
Res¢ric¢¢d income funds are those donaied for use in a particular oreo or for spe¢ifi¢ Purposes. Ihe use of which
is restrieied to that area or purpose.
Financial instruments
Cla.i.¥l}IL'ftilon
Financial assets and financial liabilities are re¢ognised when the charity becomes a party to the contractual
provision5 of the instrument.
Financial liabilitie5 and equity instruments are classified according io the substance of the contractual
arrangements eniered into. An equity instrument is any contract that evidences a residual iniere5t ii) the a55et5 of
the charity after deductin8 all of its liabilities.
2 Income from donation5 and le￿¢1¢$
Unrestricted
fund5
Restricted
fund5
Total
fund5
Donations and legacies
674.438
?38?19
91 ?.657
Tolal for 2020
674.438
?38.*19
91 ?.6.57
Total lor 2025
756.689
26) 781
1,019.470
Page 18

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
3 Income from other trading activilies
Unrestricled
funds
Restricted
Total
funds
Trading income".
Shop incotne
19.?00
19,200
Total for 2026
19.200
Total for 2025
6.4?2
6.422
4 Investment incorne
Unre51ricled
fund5
Total
fund5
Iniere5t receivable and similar income,.
Interest receivable on bank deposits
*1.851
1.85?
Total for 2026
?1.85?
?1.852
Total for 2025
19.929
19.9?9
S Expenditure on charitablc attiiities
Vnre51rict¢d
rund$
To141
2026
Tol¥l
2025
R¢stri¢t
Note
European Conference
Costs
223.654
115.704
391.934
19.681
615.588
135.385
576.752
90.771
Grants to instiiutions
Depreciation.
amortisalion and
other similar costs
sta￿ Losts
Govemance costs
6.406
231.1?4
7.490
6.406
231.124
7.490
3.432
133.689
14,085
584.378
411.615
995.993
815.729
Page 19

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
6 Analysis of Rovernance and support eosts
Governance cost5
Total
2026
Total
Audit fees
Audit of the financial staiemenis
Ind¢p¢ndent ¢xwnin¢r f¢¢s
Accounis and independent examination
Payroll fees
Bookeeping fees
1 ?.600
4.230
1.230
?.030
284
7.490
14.085
7 Net incorningloutgoing resour£¢s
Nei (ouigjoinsllincoming resources for ihe year include..
2026
2025
Audit fees
Depreciation of fiKed &%sets
6.406
3.43?
8 Trustees remuneration and expens
No trustees. nor any persons connected with them. have received any remuneration from the charity durinb the
year.
During the year. £1,410 in expenses were reimbursed to 4 Trustees (2025.. £4.784 to 4 Trustees }.
9 Staff costs
The aggregate pa>'roll costs We￿ ￿ follow5..
2026
2025
Staff cost5 during the year were:
Wage5 salaries
Social security costs
Pension costs
208,996
17,390
4.738
123,528
7,796
2.365
231.1?4
li3,689

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
The monthly average number of persons (including senior managemeni I leadership team) employed by the
charity during the year expressed by head count m.as as folloii"s=
2026
No
2025
No
Employees
No employee received emoluments of more ihan £60.000 during the year.
Th¢ totpl ¢mploy¢¢ b¢n¢fits of th¢ k¢y tn8n¥g¢m¢nt p¢rsonn¢l of th¢ charity w¢r¢ £60.7911?025- £52.4631
10 Tangible fixed assets
Computer
equipment
Total
Cost
Ai l February ?025
Additions
16.449
7.674
16.449
Ai 31 January ?026
?4.073
?4.073
tkpr¢¢ialion
Ai l F¢bruary ?025
Charge for ¢he year
8.666
6.406
8.666
6.406
At 31 January ?026
15.07?
15.07?
Net book value
At 31 January 2026
9.001
9.001
At 31 January 2025
7.783
7.783
I I Stoek
2026
Stocks
8.8?7
9.839
12 Debtor5
2026
2025
Trade debtors
Prepaytnent5
Accrued income
18.800
3?.960
12,208
45,387

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
13 Cagh and eash equivalenis
2026
2025
Cash on hand
Cash at bank
193
1.3?6.(H J
202
1,394,574
1,3*6.936
1,394.776
14 Creditors: amounts falling due within one year
2026
2025
Trade creditors
Accruals for biranis
Other taxation and social security
A¢¢ruals
D¢ferr¢d income
39.180
10• 527
5.701
13.394
168.938
3.945
26.624
?.s.000
0.000
181.559
937.901
2026
2025
tkferred in¢ome 01 l Febntary ?025
Resources deferred in the period
Amounts released from previous periods
Deferred income ai year end
?5.(M)O
?O.(M)O
!5.000
25.000
?0.000
25.000
Included wiihin deferr¢d income for 20?6 is £?O.(MIO for sponsorship for th¢ 20?6 AMMF Conf¢reii¢e.
15 Obligations under leases and hire purchase contraets
The total value of future minimum lease payments was as follows..
2026
2025
Wiihin one year
In two to five years
In over five years
43.116
7?.939
954
27.276
34.689
4.770
17,009
66,735
16 Contingent liabilitie5
At 31 January 2026 grdnts of £490.864 {20?5= £161.999) had been aw7rded of which conditions for the
recognition in the year had not been met.

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
17 Funds
CMrreNiyedr.'
Balance al I
February
2025
Balance at
31 January
2026
Incoming
r¢source5
Resources
exptnded
TraDsfers
Unre.flricledfund.f
Cicncral Funds
715,490
(593,986}
li9,114)
1.194.635
Restrieted
Restricted Research Funds
European Websiie Project
External Projects
{19,681}
13,257
77.848
86.7.$3
127.848)
66.96?
?38.?19
1391.934
Total rrslricled
147.ii9
?38.?19
i9.114
Total funds
1 ?5¢4.784
953.709
{ I.LNJ5.601 }
1 ?07.89!
Prlur J'ear..
Balanee at
Ftbruary
2024
Balanc¢ at
31 .lanuary
Incoming
resources
Resourees
expended
Transfers
Unrestricied funds
Unre.Tlricledfund.$
(iLiicral Fuiid.
954,799
783.040
{518.7941
(106.800)
1,112,245
Restricted
Restricted R¢seaTch Funds
European Websile Project
European Conference 2024
External Projecis
21,120
23.606
11.818
32.938
27.848
(7581
{?47.7631
(54.117
140,963
105.1KJO
106,800
35.870
86.753
Total restricted funds
80.596
?6? 781
30?.638
106.800
147..539
Total fund5
1.035.395
1.045.8?1
18?1.43?
1 ?59.784

AMMF - The Cholangiocarcinoma Charity
Notes to the Financial Statemellts for the Year Ended 31 January 2026
The specific purposes for which the funds are io be applied are as folloH's.'
Restricted research funds represent donaiions Mheie the donor has re4uesied ihai their donation be used for
research purposes onl>. These donations are held wiihin resiritied funds until utilised in part or in whole io fund
a cholangiocarcinoma researth projeei which the charily has commiiied io support.
Restricted funds for each of ihe major projects AMMF undertakes represent those donations or sponsorships
here ihe donor has requested that their monies be used for ihai panicular projeci only. Those funds are held as
resiricied funds uniil used in full or in part 10 compleie ihe project for which they were given.
Restricted tunds for the major. exiemal projects AMMF undertakes represeni sponsorships 10 guppon only those
individual specific projects for which the funding has bccii given. The number of such projects varies from year
to year.
The transfer of £39,114 represents restricted projects and events funded from unrestricted funds due ro a
shortfall in funding received.
18 Analy$i5 of net a55e15 between funds
Total funds at
31 January
Unmirieied
funds
Restricted
fund%
2026
Tangible fixed asse¢s
cu￿ent assels
Current liabilities
9.(M) I
1.367.193
181.559
9.001
1.380.450
181,559)
Total nei assets
1.194.635
1 ?07.89?
Total funds at
31 January
Unre5trieted
funds
Restricted
rund5
Tanbjible fixed assets
CU￿C￿t asscts
Current liabilities
7.783
1.34?.363
?37.YOI
7.783
1.489.902
{?37.YO I
147.539
Total net assets
147.539
1759.784
19 Related party tran5aCti0115
There were no related party transaciions in the year.